RespireRx Pharmaceuticals Inc. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016
July 12 2016 - 10:42PM
Marketwired
RespireRx Pharmaceuticals Inc. to Present at the Cantor
Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016
GLEN ROCK, NJ-(Marketwired - Jul 12, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for respiratory disorders,
including sleep apneas and drug-induced respiratory depression,
announced that the Company's President, CEO and Vice Chairman of
the Board of Directors, James S. Manuso, Ph.D., will present at the
Cantor Fitzgerald 2nd Annual Healthcare Conference (www.cantor.com)
in New York, New York on Wednesday, July 13, 2016, at 9:30 a.m.
Eastern Time. The Conference is being sponsored by Cantor
Fitzgerald & Co. and is being held at Le Parker Meridien Hotel,
New York, New York, on July 12 and July 13, 2016.
Commented Dr. Manuso, "The presentation at the Cantor Fitzgerald
Conference will provide RespireRx management with the opportunity
to give investors an update on RespireRx's strategic initiatives
and progress on research and development programs. I look forward
to discussing the Company's Phase 2A clinical trial testing the
impact of the oral ampakine, CX-1739, on opioid-induced respiratory
depression."
Dr. Manuso will also discuss the Company's other product
pipeline candidates, including dronabinol, and the Company's
development timelines. Dr. Manuso concluded, "We are pleased to
keep our shareholders and other stakeholders informed as to the
continuing progress of RespireRx's scientific, clinical and
regulatory development initiatives."
Dr. Manuso's slide presentation will be accessible after the
presentation on RespireRx's web-site at www.respirerx.com, by
clicking on the investors tab and following the links and
instructions. A copy of the slide presentation being presented at
the Cantor Fitzgerald Conference will be submitted in a Form 8-K
filing with the U.S. Securities and Exchange Commission prior to
the presentation.
About RespireRx Pharmaceuticals Inc.RespireRx Pharmaceuticals
Inc. is a leader in the development of medicines for respiratory
disorders, with a focus on sleep apneas and drug-induced
respiratory depression. The Company holds exclusive licenses and
owns patents and patent applications for certain families of
chemical compounds that claim the chemical structures and their use
in the treatment of a variety of disorders, as well as claims for
novel uses of known drugs.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
The first platform is the class of compounds known as
cannabinoids, in particular, dronabinol. Under a license agreement
with the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company,
dronabinol produced a statistically significant reduction in the
Apnea-Hypopnea Index, the primary therapeutic end-point, and was
observed to be safe and well-tolerated in a group of patients with
Obstructive Sleep Apnea ("OSA"). The University of Illinois and
three other centers are currently investigating dronabinol in a
potentially pivotal, six week, double-blind, placebo-controlled
Phase 2B clinical trial in 120 patients with OSA. The University of
Illinois has indicated that recruitment for this clinical trial was
completed during the second quarter of 2016. This clinical trial is
fully funded by the National Heart, Lung and Blood Institute of the
National Institutes of Health. The Company is not managing or
funding this ongoing clinical trial.
The second platform of medicines being developed by RespireRx is
a class of proprietary compounds known as ampakines, which act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptors. Several ampakines, in both oral and
injectable form, are being developed by the Company for the
treatment of a variety of breathing disorders. In clinical studies,
select ampakines have shown preliminary efficacy in central sleep
apnea and in the control of respiratory depression produced by
opioids, without altering their analgesic effects. In animal models
of orphan disorders, such as Pomp Disease, spinal cord damage and
perinatal respiratory distress, it has been demonstrated that
certain ampakines improve breathing function. The Company's
compounds belong to a new class of ampakines that do not display
the undesirable side effects previously reported in animal models
of earlier generations.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Company Contact:Jeff MargolisVice-President, Treasurer and
SecretaryTelephone: (917) 834-7206E-mail:
jmargolis@respirerx.com
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024